Release date: 2016-06-17
The systematic delivery of vaccine antigens to the dendritic cells or antigens of the immune system presents a number of technical challenges. The study reported the development of a nanoparticle RNA vaccine that preferentially targets dendritic cells after systemic administration. The vaccine consists of RNA-liposomes based on well-known lipid carriers whose orientation is achieved by optimizing the negative net charge of the nanoparticles without functionalization by molecular ligands. Intravenous administration produces long-lasting I-type interferon-dependent antigen-specific immunity in a mouse tumor model. The initial results of administration of patients with advanced melanoma indicate that the vaccine has potential efficacy in humans. Almost any tumor antigen can be encoded by RNA, so this method may have broader applicability in cancer immunotherapy.
Â
Original text search: Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Source: COO
Puyang Linshi Medical Supplies Co., Ltd. , https://www.linshimedical.com